TRCT
DAWN

Tower Research Capital (TRC)’s Day One Biopharmaceuticals DAWN Stock Holding History

Tower Research Capital (TRC)’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Buy
5,930
+4,296
+263% +$60.5K ﹤0.01% 1991
2025
Q4 		$15.2K Sell
1,634
-11,518
-88% -$96.2K ﹤0.01% 3302
2025
Q3 		$92.7K Buy
13,152
+7,908
+151% +$54.4K ﹤0.01% 2047
2025
Q2 		$34.1K Buy
5,244
+3,326
+173% +$22.9K ﹤0.01% 3307
2025
Q1 		$15.2K Sell
1,918
-8,739
-82% -$94.1K ﹤0.01% 3232
2024
Q4 		$135K Buy
10,657
+9,603
+911% +$134K ﹤0.01% 1978
2024
Q3 		$14.7K Sell
1,054
-22,595
-96% -$322K ﹤0.01% 3446
2024
Q2 		$326K Buy
23,649
+21,949
+1,291% +$321K 0.01% 1692
2024
Q1 		$28.1K Sell
1,700
-205
-11% -$3.07K ﹤0.01% 2706
2023
Q4 		$27.8K Buy
1,905
+212
+13% +$2.57K ﹤0.01% 3462
2023
Q3 		$20.8K Sell
1,693
-1,478
-47% -$19.3K ﹤0.01% 3337
2023
Q2 		$37.9K Sell
3,171
-3,615
-53% -$47.2K ﹤0.01% 2818
2023
Q1 		$91K Buy
6,786
+4,350
+179% +$85K ﹤0.01% 1951
2022
Q4 		$53K Buy
2,436
+250
+11% +$5.13K ﹤0.01% 2299
2022
Q3 		$44K Sell
2,186
-1,564
-42% -$33.3K ﹤0.01% 3275
2022
Q2 		$67K Buy
3,750
+1,940
+107% +$20K ﹤0.01% 2616
2022
Q1 		$18K Buy
1,810
+763
+73% +$10.1K ﹤0.01% 3618
2021
Q4 		$17K Buy
1,047
+513
+96% +$10.5K ﹤0.01% 3842
2021
Q3 		$12K Buy
534
+524
+5,240% +$12.6K ﹤0.01% 4139
2021
Q2 		$0 Buy
+10
New +$209 ﹤0.01% 5526

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Tower Research Capital (TRC)'s DAWN Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Day One Biopharmaceuticals (DAWN) stake by 263% in Q1 2026, buying an estimated $60.5K and bringing the position to 5,930 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1991.

Tower Research Capital (TRC) first reported a position in DAWN in Q2 2021 and has held it in 20 quarters since. The position peaked at $326K in Q2 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Tower Research Capital (TRC) held 5,930 shares of Day One Biopharmaceuticals worth $127K as of Q1 2026.
  • Tower Research Capital (TRC) bought 4,296 Day One Biopharmaceuticals shares in Q1 2026, an estimated $60.5K.
  • Day One Biopharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1991 holding.
  • Tower Research Capital (TRC) first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Day One Biopharmaceuticals position peaked at $326K in Q2 2024.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.